Fanny Sie

My Virtual Dream publishes PLOS study on Nuit Blanche results

“My Virtual Dream” is an innovative and interactive live performance experience of the Virtual Brain technology developed by researchers at Baycrest Health Sciences Centre in partnership with neuroscience experts around the world.

Baycrest Heath Sciences’ “My Virtual Dream,” an innovative and interactive live performance experience at the intersection of science, art and music, is currently touring the installation with appearances in Amsterdam in May and more scheduled for Irvine, CA in October.

MaRS Innovation is working with the Baycrest team to commercialize the technology behind the demonstration, known as the virtual brain.

My Virtual Dream was featured in TechVibes on July 8 and in a PLOS blog published on August 14, 2015.

“The Virtual Dream tour is a ‘living lab’ that engages the public, fuels science, creates art and educates while it entertains,” says Richard Tavener, executive producer of the Virtual Dream tour.

The exhibition and research project was originally mounted in partnership with the University of Toronto, Nuit Blanche 2013, and InteraXon and also made a January 2015 appearance at the Ontario Science Centre.

Participants wear the Muse, a brain-computer interface headset provided by InteraXon, and use focus and mental relaxation states to complete a science game and create a stunning array of visuals and music.

The brain data collected at Nuit Blanche has yielded insights about how the brain learns and a science paper about this massive, one-night neuroscience experiment. The paper, which appeared in the July issue of PLOS One, found that:

MI’s head of imaging technologies quoted on bioprinting in U.K.’s Financial Times

Fanny Sie, MaRS Innovation’s head of imaging technologies, was quoted in Tanya Powley‘s article, “Printing whole organs remains a long way off,” for the U.K.’s Financial Times on June 11, 2015, regarding the technology’s potential to transform existing healthcare practices.

MI does wish to note that the article inaccurately attributes the PrintAlive device’s development to MaRS Innovation; MI is working with the University of Toronto inventing team, led by Dr. Axel Gunther, to commercialize the device.

Here’s a short excerpt:

Bioprinting could save pharmaceutical companies a lot of money, according to Fanny Sie of MaRS Innovation, a Toronto-based company. The company has developed the PrintAlive Bioprinter, which can print skin that could be used to treat people with large scale burns. The printed tissues could be used by pharmaceutical companies to test the toxicity of new drugs, and help them decide if it is worth starting costly animal and then human clinical trials.

BlueDot, formerly BioDiaspora Inc., secures Series A with Horizons Ventures

December 2, 2014
Susanne Staer
BlueDot

Toronto-based commercial arm of BioDiaspora research program tracks global spread of infectious diseases in real-time; fourth MI company to reach Series A

TORONTO (Dec. 2, 2014) — BlueDot, a Toronto-based social benefit corporation founded by Dr. Kamran Khan, an infectious disease physician and scientist, tracks and predicts the global spread of infectious diseases.

Spun off from St. Michael’s Hospital in partnership with MaRS Innovation (and formerly known as BioDiaspora Inc.), BlueDot, has secured a Series A venture capital funding from Horizons Ventures. Funded by Sir Li Ka-shing, Horizons invests in what they call “game-changing disruptive tech,” and has a proven track record in making early-stage investments (i.e., Facebook, Skype, Waze, Siri and Spotify).

TechVibes and MedCity News covered BlueDot’s Series A announcement, as did PE Hub and BetaKit. Read the BlueDot press release here.

The company is the fourth in MaRS Innovation’s portfolio to reach Series A. MaRS Innovation provided $400,000 in seed funding and worked with BlueDot and St. Michael’s to incorporate the company and develop its initial business strategy, intellectual property protection strategy and go-to-market plan. The Ontario Centres of Excellence also provided $140,000 in commercialization grants that helped BlueDot get off the ground.

BlueDot is the commercial arm of Dr. Khan’s academic research program called BioDiaspora, which was developed at the Li Ka Shing Knowledge Institute of St. Michael’s. BioDiaspora models how infectious diseases can spread and impact populations globally by analyzing big data such as the annual movements of more than 3 billion travelers on commercial flights; human, animal and insect population data; climate data from satellites; and news reports of disease outbreaks. The program was inspired by the Toronto’s SARS crisis in 2003 and its capabilities scientifically validated in prestigious academic journals such as the Lancet and the New England Journal of Medicine.

Visualization of the final destinations of travellers departing countries in West Africa with widespread and intense Ebola virus transmission — Visualization of the final destinations of travelers departing countries in West Africa with widespread and intense Ebola virus transmission. Source: http://bluedot.global/work

During its development, BlueDot’s platform technology was used by numerous international agencies, including the U.S. Centers for Disease Control, the World Health Organization, the European Centre for Disease Prevention and Control and the Public Health Agency of Canada to evaluate emerging infectious disease threats, including those during global mass gatherings such as the Olympics and the hajj.

MI’s Fanny Sie to speak about 3D printing trends at two Toronto events

May 8, 2014
Susanne Staer
News

Fanny-Sie-web-7227 — **Fanny Sie** is a manager in MI’s Technology & Venture Development group and head, Imaging Technologies Area.

Fanny Sie, MaRS Innovation’s head of imaging technologies and a manager in the Technology & Venture Development group, is speaking about bioprinting trends at two Toronto conferences this weekend.

Sie is MI’s commercialization lead on the Bioprinter, a licensenable technology from the University of Toronto and Sunnybrook Health Sciences Centre.

Watch her interview on bioprinting with TVO’s The Agenda, which aired in June 2013.

First up is Digifest, an international festival celebrating digital creativity, which runs from May 8 to 10 at the Corus Quay building on Toronto’s Waterfront. Sie will speak about 3D printing and its biological and commercial implications on the Mass Customization Panel Discussion, which runs from 2 to 3 pm on Friday, May 9.

On Monday, Sie joins the opening panel at the OCE Discovery Conference, which runs from May 12 to 13, 2014 at the Metro Toronto Convention Centre (South Building). She will speak during the “3D Manufacturing: Beyond the Hype” panel at 9 am on May 13.

Bioprinter covered on CTV’s Canada AM

January 30, 2014
Susanne Staer
Media Coverage

The Bioprinter project, a three-way initiative from MaRS Innovation, the University of Toronto and Sunnybrook Health Sciences Centre, was featured on Canada AM on January 29 during a segment with…

Yonge Street Media Highlights MaRS Innovation Bioprinter Project

December 5, 2013
Susanne Staer
Media Coverage

MI Project Manger Fanny Sie discusses Toronto’s impact on 3D printing landscape

In a December 4 article, part of a feature series on technology in Toronto, Yonge Street Media reporter Andrew Seale highlights the creative and innovative technological work surrounding the 3D printing and cyber security sectors in the city.

MaRS Innovation’s Fanny Sie is managing business development for the Bioprinter, a 3D printer using University of Toronto technology that’s capable of printing on organic material, including skin.

By printing on skin, the cost of treating burns on the body could be reduced.

Here’s an excerpt from the article (links and emphasis ours):

“Cells are very intelligent, you just have to be able to put them close enough to one another in order for them to take over,” says Sie adding that some of the research is a partnership with the Sunnybrook Health Sciences Centre and Research Institute.

Bringing mad science to mass production: Financial Post features the Bio Printer project

University of Toronto PhD student Lian Len with a prototype tissue printer. Photo courtesy of Dominic Ali (University of Toronto)

“It’s one thing to invent a machine that prints skin, but it’s a whole other challenge to bring what seems like the domain of mad science to mass production,” Matthew Braga wrote in “Looking for ways to get ‘skin’ in the game,” published in the Financial Post on July 15.

The article focuses on MaRS Innovation’s (MI) and the Innovations and Partnerships Office’s (University of Toronto) joint efforts to commercialize the bio printer, a “prototype 3D printer that, instead of extruding layers of plastic and other inorganic materials into physical shapes, builds layer upon layer of cell-laden tissue, a process that could lead to the cheap, rapid production of human skin.”

Braga’s article was syndicated in the Regina Leader Post, the Saskatoon Star-Phoenix, and the Vancouver Sun, among other Canadian publications.

MaRS Innovation on The Agenda’s 3D Printing Epsiode

MI’s Fanny Sie and Shotlst Co-founder Matt Ratto talk bioprinting, healthcare, civil rights and home manufacturing with Steve Paikin

Fanny Sie, project manager in physical sciences and medical devices with specialization in medical imaging, appeared on TVO’s The Agenda on June 5, 2013 to discuss 3D printing.

MaRS Innovation Project Manager Fanny Sie discusses 3D printing, the Bioprinter technology and the implications for society and human health on TVO’s The Agenda.

Click here to watch Fanny Sie on The Agenda.

Sie manages the Bioprinter technology, which was touched upon during the interview. The bioprinter was invented by Axel Guenther, a professor in the University of Toronto’s Department of Mechanical and Industrial Engineering, PhD student Lian Leng and a team of other researchers.

The Globe and Mail covered the Bioprinter’s development on January 20, 2013; an excerpt of their interviews with Leng and Guenther was included in the program.

Bioprinting and the Internet of Things

The Agenda’s 3D printing episode also included a second segment exploring its implications for home manufacturing and civil liberties. The guests included Matt Ratto, assistant professor in U of T’s Faculty of Information and co-inventor and CEO of Shotlst (a UTEST company).

Professor Matt Ratto, co-founder of Shotlst and director of the Critical Making Lab, discusses 3D printing, home manufacturing and civil liberties on TVO’s The Agenda.

Click here to watch Professor Matt Ratto on The Agenda.

Ratto described his experience downloading and printing the Liberator, a gun that can be printed using 3D printing technology, to better understand the process required and the resulting gun’s capabilities.

MI’s Fanny Sie and Shotlst Founder Matt Ratto to appear on TVO’s The Agenda 8 pm

Fanny Sie, project manager, MaRS Innovation — **Fanny Sie**, project manager in physical sciences and medical devices , MaRS Innovation.

MaRS Innovation’s Fanny Sie, project manager in physical sciences and medical devices with specialization in medical imaging, is appearing on TVO’s The Agenda with Steve Paikin at 8 pm on June 5, 2013 to discuss 3D printing and the technology’s applications in healthcare and other aspects of human society.

Sie manages the Bioprinter technology, which was invented by Axel Guenther, a professor in the University of Toronto’s Department of Mechanical and Industrial Engineering, PhD student Lian Leng and a team of other researchers. The Globe and Mail covered the Bioprinter’s development on January 20, 2013.

What does MaRS Innovation’s funding extension mean for Toronto’s academic entrepreneurs?

Every six weeks, MaRS Innovation’s marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI’s activities or one of our start-up companies. You can read the original post on the MaRS blog.

Created in 2008, MaRS Innovation (MI) bridges the chasm between the early-stage technologies emerging from its 16 member institutions and successful startup companies and licensable technologies.

By offering early-stage funding in tandem with hands-on management, business development, mentorship and intellectual property protection strategy, MI acts as a commercialization agent for its members and researchers.

Earlier this year, the Networks of Centres of Excellence of Canada awarded MI $14.95 million to continue its mandate as a Centre of Excellence for Commercialization and Research (CECR), matched by $25 million from membership fees and private sector investments.

So what does that success mean for MI’s ability to serve the needs of academic entrepreneurs based in Toronto?

My Virtual Dream publishes PLOS study on Nuit Blanche results

MI’s head of imaging technologies quoted on bioprinting in U.K.’s Financial Times

BlueDot, formerly BioDiaspora Inc., secures Series A with Horizons Ventures

Toronto-based commercial arm of BioDiaspora research program tracks global spread of infectious diseases in real-time; fourth MI company to reach Series A

MI’s Fanny Sie to speak about 3D printing trends at two Toronto events

Bioprinter covered on CTV’s Canada AM

Yonge Street Media Highlights MaRS Innovation Bioprinter Project

MI Project Manger Fanny Sie discusses Toronto’s impact on 3D printing landscape

Bringing mad science to mass production: Financial Post features the Bio Printer project

MaRS Innovation on The Agenda’s 3D Printing Epsiode

MI’s Fanny Sie and Shotlst Co-founder Matt Ratto talk bioprinting, healthcare, civil rights and home manufacturing with Steve Paikin

Bioprinting and the Internet of Things

MI’s Fanny Sie and Shotlst Founder Matt Ratto to appear on TVO’s The Agenda 8 pm

What does MaRS Innovation’s funding extension mean for Toronto’s academic entrepreneurs?

Quick Links

Contact Us